A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

被引：165

作者：

Ledgerwood, J. E. ^{[1
]}

Costner, P. ^{[1
]}

Desai, N. ^{[1
]}

Holman, L. ^{[1
]}

Enama, M. E. ^{[1
]}

Yamshchikov, G. ^{[1
]}

Mulangu, S. ^{[1
]}

Hu, Z. ^{[1
]}

Andrews, C. A. ^{[1
]}

Sheets, R. A. ^{[1
]}

Koup, R. A. ^{[1
]}

Roederer, M. ^{[1
]}

Bailer, R. ^{[1
]}

Mascola, J. R. ^{[1
]}

Pau, M. G. ^{[2
]}

Sullivan, N. J. ^{[1
]}

Goudsmit, J. ^{[2
]}

Nabel, G. J. ^{[1
]}

Graham, B. S. ^{[1
]}

机构：

[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

[2] Crucell Holland BV, Leiden, Netherlands

来源：

VACCINE | 2010年 / 29卷 / 02期

关键词：

Adenovirus; Gene-based vaccines; Ebola; Filovirus vaccine; TYPE-1 GAG GENE; ADENOVIRUS VECTORS; NONHUMAN-PRIMATES; HIV-1; VACCINE; OF-CONCEPT; CANDIDATE VACCINE; HEMORRHAGIC-FEVER; INDUCED IMMUNITY; PHASE-1; SAFETY; RHESUS-MONKEYS;

D O I：

10.1016/j.vaccine.2010.10.037

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Ebola virus causes irregular outbreaks of severe hemorrhagic fever in equatorial Africa. Case mortality remains high; there is no effective treatment and outbreaks are sporadic and unpredictable. Studies of Ebola virus vaccine platforms in non-human primates have established that the induction of protective immunity is possible and safety and human immunogenicity has been demonstrated in a previous Phase I clinical trial of a 1st generation Ebola DNA vaccine. We now report the safety and immunogenicity of a recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, in a randomized, placebo-controlled, double-blinded, dose escalation, Phase I human study. Thirty-one healthy adults received vaccine at 2 x 10(9) (n = 12), or 2 x 10(10) (n = 11) viral particles or placebo (n = 8) as an intramuscular injection. Antibody responses were assessed by ELISA and neutralizing assays; and T cell responses were assessed by ELISpot and intracellular cytokine staining assays. This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses. Published by Elsevier Ltd.

引用

页码：304 / 313

页数：10

共 11 条

[1] NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults
Schmidt, Clint S.
White, C. Jo
Ibrahim, Ashraf S.
Filler, Scott G.
Fu, Yue
Yeaman, Michael R.
Edwards, John E., Jr.
Hennessey, John P., Jr.
VACCINE, 2012, 30 (52) : 7594 - 7600
[2] Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial
ElSherif, May S.
Brown, Catherine
MacKinnon-Cameron, Donna
Li, Li
Racine, Trina
Alimonti, Judie
Rudge, Thomas L.
Sabourin, Carol
Silvera, Peter
Hooper, Jay W.
Kwilas, Steven A.
Kilgore, Nicole
Badorrek, Christopher
Ramsey, W. Jay
Heppner, D. Gray
Kemp, Tracy
Monath, Thomas P.
Nowak, Teresa
McNeil, Shelly A.
Langley, Joanne M.
Halperin, Scott A.
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2017, 189 (24) : E819 - E827
[3] A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge
Reynolds, Matthew R.
Weiler, Andrea M.
Piaskowski, Shari M.
Piatak, Michael, Jr.
Robertson, Henry T.
Allison, David B.
Bett, Andrew J.
Casimiro, Danilo R.
Shiver, John W.
Wilson, Nancy A.
Lifson, Jeffrey D.
Koff, Wayne C.
Watkins, David I.
VACCINE, 2012, 30 (30) : 4465 - 4475
[4] Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
Halperin, Scott A.
Arribas, Jose R.
Rupp, Richard
Andrews, Charles P.
Chu, Laurence
Das, Rituparna
Simon, Jakub K.
Onorato, Matthew T.
Liu, Kenneth
Martin, Jason
Helmond, Frans A.
JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (12) : 1789 - 1798
[5] Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer
Li, Yuhua
Wang, Ling
Zhu, Tao
Wu, Shipo
Feng, Liqiang
Cheng, Ping
Liu, Jingjing
Wang, Junzhi
HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2018, 29 (04) : 226 - 232
[6] Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults
Moutschen, Michel
Leonard, Philippe
Sokal, Etienne M.
Smets, Francoise
Haumont, Michele
Mazzu, Pasqualina
Bollen, Alex
Denamur, Francoise
Peeters, Pascal
Dubin, Gary
Denis, Martine
VACCINE, 2007, 25 (24) : 4697 - 4705
[7] Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
Dolzhikova, I. V.
Zubkova, O. V.
Tukhvatulin, A. I.
Dzharullaeva, A. S.
Tukhvatulina, N. M.
Shcheblyakov, D. V.
Shmarov, M. M.
Tokarskaya, E. A.
Simakova, Y. V.
Egorova, D. A.
Scherbinin, D. N.
Tutykhina, I. L.
Lysenko, A. A.
Kostarnoy, A. V.
Gancheva, P. G.
Ozharovskaya, T. A.
Belugin, B. V.
Kolobukhina, L. V.
Pantyukhov, V. B.
Syromyatnikova, S. I.
Shatokhina, I. V.
Sizikova, T. V.
Rumyantseva, I. G.
Andrus, A. F.
Boyarskaya, N. V.
Voytyuk, A. N.
Babira, V. F.
Volchikhina, S. V.
Kutaev, D. A.
Bel'skih, A. N.
Zhdanov, K. V.
Zakharenko, S. M.
Borisevich, S. V.
Logunov, D. Y.
Naroditsky, B. S.
Gintsburg, A. L.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (03) : 613 - 620
[8] Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Zhu, Feng-Cai
Hou, Li-Hua
Li, Jing-Xin
Wu, Shi-Po
Liu, Pei
Zhang, Gui-Rong
Hu, Yue-Mei
Meng, Fan-Yue
Xu, Jun-Jie
Tang, Rong
Zhang, Jin-Long
Wang, Wen-Juan
Duan, Lei
Chu, Kai
Liang, Qi
Hu, Jia-Lei
Luo, Li
Zhu, Tao
Wang, Jun-Zhi
Chen, Wei
LANCET, 2015, 385 (9984) : 2272 - 2279
[9] Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Li, Jing-Xin
Hou, Li-Hua
Meng, Fan-Yue
Wu, Shi-Po
Hu, Yue-Mei
Liang, Qi
Chu, Kai
Zhang, Zhe
Xu, Jun-Jie
Tang, Rong
Wang, Wen-Juan
Liu, Pei
Hu, Jia-Lei
Luo, Li
Jiang, Rong
Zhu, Feng-Cai
Chen, Wei
LANCET GLOBAL HEALTH, 2017, 5 (03): : E324 - E334
[10] HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates
Garcia-Arriaza, Juan
Perdiguero, Beatriz
Heeney, Jonathan L.
Seaman, Michael S.
Montefiori, David C.
Yates, Nicole L.
Tomaras, Georgia D.
Ferrari, Guido
Foulds, Kathryn E.
Roederer, Mario
Self, Steven G.
Borate, Bhavesh
Gottardo, Raphael
Phogat, Sanjay
Tartaglia, Jim
Barnett, Susan W.
Burke, Brian
Cristillo, Anthony D.
Weiss, Deborah E.
Lee, Carter
Kibler, Karen V.
Jacobs, Bertram L.
Wagner, Ralf
Ding, Song
Pantaleo, Giuseppe
Esteban, Mariano
JOURNAL OF VIROLOGY, 2017, 91 (09)

← 1 2 →